First Prognostic Test for IBD Now Available for Patients in the UK and Ireland

First Prognostic Test for IBD Now Available for Patients in the UK and Ireland
PredictImmune's prognostic test for inflammatory bowel disease (IBD) is now available to clinicians and gastroenterologists in the U.K. and Ireland, the company announced. Developed in partnership with the University of Cambridge, the assay, called PredictSURE IBD, is the first validated predictive test for IBD, including Crohn's disease and ulcerative colitis, to become available for the public. Results supporting the test were published in the study titled "A blood-based prognostic biomarker in IBD" in the journal Gut. "We are excited to see PredictSURE IBD become available to U.K. and Irish patients, particularly because we understand the life-changing benefits that early and accurate prediction of the likely course of their IBD disease can have on their quality of life,” Paul Kinnon, PredictImmune’s CEO, said in a press release. IBD is an autoimmune disease with a range of symptoms. Some patients have a severe form of the disease, experiencing frequent flares and needing strong medications, while others have a milder form with infrequent flares. Predicting the outcome of the disease is crucial to providing patients with appropriate and personalized treatment. To do this, it is necessary to identify biomarkers that predict disease outcome. Researchers at the University of Cambridge discovered that the T cells CD8+ (a type of immune cell) had a set of biomarkers with a genetic signature that differentiated patients with severe IBD from those with the mild form of the disease at the time of diagnosis. To identify this genetic signature, the researchers investigated the genetic profile of 69 Crohn's disease patients and then validated their findings in 123 patients with IBD recruited from clinics around England. This 10-year study led to the
Subscribe or to access all post and page content.